Translational Oncology Biomarkers

Abstract

Translational oncology biomarkers bridge the gap between tumour biology discovery and clinical application, guiding diagnosis, prognosis, treatment selection, and response monitoring across the expanding armamentarium of cancer therapies. The past decade has witnessed explosive growth in candidate biomarkers -- from traditional immunohistochemistry markers through molecular alterations, gene expression signatures, circulating tumour DNA kinetics, microbiome composition, and multi-modal imaging-pathology-molecular composites -- but the translation from biomarker discovery to validated clinical utility has been slower and more variable than the pace of discovery might suggest. Understanding which translational pathways most efficiently convert biomarker candidates into clinically useful tools is essential for prioritising limited biomarker qualification resources. We evaluated five translational oncology biomarker pathway frameworks applied to 186 biomarker programmes across 22 European academic cancer centres and industry sites in Paris, Rome, Stockholm, Barcelona, and Heidelberg between 2012 and 2024. Frameworks ranged from single-laboratory discovery through fully integrated consortium development with companion diagnostic co-development and regulatory qualification. Performance was benchmarked using our Translational Oncology Biomarker Effectiveness Score (TOBES), integrating analytical validation rigour, clinical validation breadth, clinical utility demonstration, regulatory qualification achievement, and implementation reach. The fully integrated consortium framework achieved the highest TOBES (0.918), reducing time from biomarker discovery to companion diagnostic approval from 7.8 years to 3.4 years and achieving clinical implementation in 78.4% of European oncology centres versus 32.4% for single-laboratory development. ctDNA-based minimal residual disease biomarkers and multi-gene tumour profiling panels exemplified successful integrated translation.